pre_text: edwards lifesciences corporation notes to consolidated financial statements ( continued ) 7 . acquisitions ( continued ) transaction closed on january 23 , 2017 , and the consideration paid included the issuance of approximately 2.8 million shares of the company 2019s common stock ( fair value of $ 266.5 million ) and cash of $ 86.2 million . the company recognized in 201ccontingent consideration liabilities 201d a $ 162.9 million liability for the estimated fair value of the contingent milestone payments . the fair value of the contingent milestone payments will be remeasured each quarter , with changes in the fair value recognized within operating expenses on the consolidated statements of operations . for further information on the fair value of the contingent milestone payments , see note 10 . in connection with the acquisition , the company placed $ 27.6 million of the purchase price into escrow to satisfy any claims for indemnification made in accordance with the merger agreement . any funds remaining 15 months after the acquisition date will be disbursed to valtech 2019s former shareholders . acquisition-related costs of $ 0.6 million and $ 4.1 million were recorded in 201cselling , general , and administrative expenses 201d during the years ended december 31 , 2017 and 2016 , respectively . prior to the close of the transaction , valtech spun off its early- stage transseptal mitral valve replacement technology program . concurrent with the closing , the company entered into an agreement for an exclusive option to acquire that program and its associated intellectual property for approximately $ 200.0 million , subject to certain adjustments , plus an additional $ 50.0 million if a certain european regulatory approval is obtained within 10 years of the acquisition closing date . the option expires two years after the closing date of the transaction , but can be extended by up to one year depending on the results of certain clinical trials . valtech is a developer of a transcatheter mitral and tricuspid valve repair system . the company plans to add this technology to its portfolio of mitral and tricuspid repair products . the acquisition was accounted for as a business combination . tangible and intangible assets acquired were recorded based on their estimated fair values at the acquisition date . the excess of the purchase price over the fair value of net assets acquired was recorded to goodwill . the following table summarizes the fair values of the assets acquired and liabilities assumed ( in millions ) : .
post_text: goodwill includes expected synergies and other benefits the company believes will result from the acquisition . goodwill was assigned to the company 2019s rest of world segment and is not deductible for tax purposes . ipr&d has been capitalized at fair value as an intangible asset with an indefinite life and will be assessed for impairment in subsequent periods . the fair value of the ipr&d was determined using the income approach . this approach determines fair value based on cash flow projections which are discounted to present value using a risk-adjusted rate of return . the discount rates used to determine the fair value of the ipr&d ranged from 18.0% ( 18.0 % ) to 20.0% ( 20.0 % ) . completion of successful design developments , bench testing , pre-clinical studies .
table: Current assets $22.7
table: Property and equipment, net 1.2
table: Goodwill 316.5
table: Developed technology 109.2
table: IPR&D 87.9
table: Other assets 0.8
table: Current liabilities assumed (5.1)
table: Deferred income taxes (17.6)
table: Total purchase price 515.6
table: Less: cash acquired (4.3)
table: Total purchase price, net of cash acquired $511.3
question: Analyse this data from a financial earnings document. what are the acquisition-related costs recorded in 201cselling , general , and administrative expenses 201d as a percentage of current assets?